Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.
Vaccinex, Inc. (VCNX) is a clinical-stage biotechnology company headquartered in Rochester, NY. Specializing in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines, and other biologic products, Vaccinex is dedicated to addressing serious diseases with unmet medical needs, including cancer, multiple sclerosis, and other autoimmune diseases.
The company is pioneering a unique approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). Vaccinex's leading drug candidate, pepinemab, is designed to block SEMA4D, a potent agent believed to prevent immune infiltration into tumors and reduce inflammation in chronic brain diseases. Currently, pepinemab is undergoing evaluation in a Phase 1b/2 study for recurrent or metastatic head and neck cancer and in a Phase 1/2a study for Alzheimer’s Disease. Additionally, there is ongoing exploration for potential Phase 3 development in Huntington's disease.
Vaccinex conducts research both in-house and through collaborations with prominent academic institutions and biotechnology firms. The company's proprietary drug discovery platform, ActivMAb, plays a significant role in its innovative drug development approach. The development team at Vaccinex comprises experienced industry veterans skilled in therapeutic biologics research, manufacturing, quality control, toxicology, pharmacology, regulatory affairs, and clinical affairs.
Recently, Vaccinex has achieved notable milestones, including a 1-for-15 reverse stock split to regain compliance with Nasdaq listing standards and the advancement of its clinical trials. The company continues to secure funding for its research, with significant investments from the Alzheimer’s Drug Discovery Foundation and grants from the Alzheimer’s Association.
Vaccinex remains committed to advancing its clinical programs and expanding its pipeline of innovative therapies to improve patient outcomes in challenging diseases.
Vaccinex, Inc. (Nasdaq: VCNX) announced that Elizabeth Evans, PhD, will chair a symposium and present a poster at the XV European Meeting on Glial Cells in Health and Disease, held virtually from July 5 to 9, 2021. The symposium focuses on targeting glial cell activation for neurodegenerative disease treatment. Dr. Evans will discuss the clinical evaluation of pepinemab, a SEMA4D blocking antibody for Huntington's Disease and its Phase 1b/2a trial in Alzheimer’s Disease. The poster presentation will detail findings from these clinical trials.
Vaccinex (Nasdaq: VCNX) announced the activation of clinical sites for two significant studies. They aim to enroll at least 40 patients in a Phase 1/2 Alzheimer’s study evaluating pepinemab and 65 patients in a Phase 2 study assessing pepinemab in combination with Merck’s KEYTRUDA for advanced head and neck squamous cell carcinoma. Notable support comes from the Alzheimer’s Drug Discovery Foundation. The studies will measure cognition, brain imaging, and various efficacy endpoints, crucial for developing new therapies in neurodegenerative diseases and cancer.
Vaccinex, Inc. (Nasdaq: VCNX) announced that CEO Dr. Maurice Zauderer will present at the 2021 Jefferies Virtual Healthcare Conference from June 1-4, 2021. The presentation is scheduled for June 1 at 4:30 PM ET, focusing on advancements in Vaccinex's neurology programs targeting Huntington’s and Alzheimer’s diseases, and their collaboration with Merck for head and neck cancer immunotherapy using pepinemab and KEYTRUDA®. A live video webcast will be available on the Vaccinex website post-presentation.
Vaccinex, Inc. (VCNX) has initiated a Phase 2 study of pepinemab combined with KEYTRUDA® for advanced head and neck cancer. The company announced positive results from the CLASSICAL-Lung trial published in Clinical Cancer Research, showing pepinemab's clinical activity in non-small cell lung cancer. Financially, Vaccinex raised $32 million through an open sale market agreement. For Q1 2021, revenue reached $850,000, with R&D expenses of $5.5 million. The company plans to start a Phase 1/2a trial for Alzheimer’s disease by Q2 2021.
Vaccinex, Inc. (Nasdaq: VCNX) announced the publication of results from its CLASSICAL-Lung clinical trial, evaluating pepinemab in combination with BAVENCIO® for treating non-small cell lung cancer (NSCLC). The Phase 1b/2 trial demonstrated clinical activity and safety, with a disease control rate (DCR) of 81% among immunotherapy naïve patients and 59% among those resistant to prior therapies. The results indicate that pepinemab may enhance the efficacy of checkpoint inhibitors, especially in challenging cases including PD-L1 negative tumors. The full data set is published in Clinical Cancer Research.
Vaccinex, Inc. (Nasdaq: VCNX) reported top-line results from the SIGNAL Phase 2 study showing potential cognitive benefits of pepinemab in Huntington's disease. The company plans to initiate a Phase 1b/2 study of pepinemab with KEYTRUDA® for head and neck cancer and an Alzheimer’s trial in Q2 2021. In Q1 2021, Vaccinex raised $32 million through an open market sale agreement. Revenue increased to $625,000 in 2020, while R&D expenses decreased to $21.5 million. The company anticipates pivotal trial partnerships for Huntington’s disease and has significant funding for upcoming studies.
Vaccinex, Inc. (Nasdaq: VCNX) announced that CEO Dr. Maurice Zauderer will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, from 2:30 to 3:00 PM ET. The presentation will cover the company's innovative approach to treating cancer and neurodegenerative diseases by targeting SEMA4D. A live webcast will be available for interested investors and stakeholders. Vaccinex's lead drug candidate, pepinemab, aims to enhance immune responses against tumors while addressing chronic inflammation in the brain.
Vaccinex, Inc. (Nasdaq: VCNX) announced that Surface Oncology will license the anti-CCR8 antibody, SRF114, discovered via Vaccinex’s ActivMAb platform. The agreement entails licensing fees, research funding, development milestone payments, and royalties for Vaccinex. SRF114 targets tumor T regulatory cells, potentially enhancing immunotherapy efficacy. The ActivMAb platform has applications in discovering antibodies against complex antigens. Vaccinex's lead candidate, pepinemab, aims to treat neurodegenerative diseases by inhibiting SEMA4D, which is linked to neuroinflammation.
Vaccinex has partnered with two undisclosed pharmaceutical companies to leverage its ActivMAb® platform for antibody discovery, focusing on complex antigens like GPCRs and ion channels. These collaborations aim to enhance vaccine development and therapeutic solutions. The terms of these agreements remain undisclosed. The ActivMAb technology is known for its ability to identify unique antibodies against challenging targets, which could lead to advancements in treatment options for various diseases. Vaccinex's lead candidate, pepinemab, is also highlighted for its potential in treating neurodegenerative diseases.
Vaccinex (Nasdaq: VCNX) announced its participation in the 10th Annual LifeSci Partners Corporate Access Event from January 6-8 and 11-14, 2021. Maurice Zauderer, Ph.D., will present a corporate update and host 1x1 meetings on January 6th at 11 am EST. The company is focused on treating neurodegenerative diseases with its lead candidate, pepinemab, which inhibits SEMA4D. Pepinemab shows promise for conditions like Huntington’s and Alzheimer’s and is in trials with checkpoint inhibitors for oncology applications.
FAQ
What is the current stock price of Vaccinex (VCNX)?
What is the market cap of Vaccinex (VCNX)?
What is Vaccinex, Inc.?
Where is Vaccinex, Inc. located?
What is Vaccinex's lead drug candidate?
What is the focus of Vaccinex's research?
What clinical studies is pepinemab involved in?
What is the ActivMAb platform?
Who are Vaccinex's research partners?
What recent milestone has Vaccinex achieved?
How is Vaccinex funded?
Who leads the development team at Vaccinex?
